Known targets — ChEMBL curated mechanism
CACNA1BGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BMAOBSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Ralfinamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A known ✓ | Q15858 | 2/20 | 0.91 |
| ▸ | MAOB known ✓ | P27338 | 6/20 | 0.62 |
| ▸ | SCN3A known ✓ | Q9NY46 | 2/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.53 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ralfinamide SCHEMBL1697229 | 1.00 | SCN9A (0.91) | SCN9AMAOBMAOASCN3APARP15 | |
| Ralfinamide SCHEMBL1697234 | 1.00 | SCN9A (0.91) | SCN9AMAOBMAOASCN3APARP15 | |
| Ralfinamide SCHEMBL29379049 | 0.96 | SCN9A (1.00) | SCN9AMAOBMAOASCN3APARP15 | |
| Ralfinamide SCHEMBL67328 | 0.96 | SCN9A (1.00) | SCN9AMAOBMAOASCN3APARP15 | |
| Ralfinamide SCHEMBL67329 | 0.96 | SCN9A (1.00) | SCN9AMAOBMAOASCN3APARP15 | |
| Ralfinamide SCHEMBL962699 | 0.96 | SCN9A (1.00) | SCN9AMAOBMAOASCN3APARP15 | |
| Ralfinamide SCHEMBL1697253 | 0.94 | SCN9A (0.98) | SCN9AMAOBMAOASCN3APARP15 | |
| Ralfinamide SCHEMBL1697252 | 0.94 | SCN9A (0.98) | SCN9AMAOBMAOASCN3APARP15 | |
| SCHEMBL8638247 | 0.90 | SCN9A (0.74) | SCN9AMAOBMAOASCN3AHRH3 | |
| SCHEMBL963787 | 0.88 | SCN9A (0.85) | SCN9AMAOBMAOASCN3APARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12533309-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12527729-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250360128-A1 | MINOXIDIL ADJUVANT THERAPIES | JUPITER WELLNESS INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4536354-A1 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240009101-A1 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. (US) | 2024-01-11 | — | — | US | disclosed |
| US-20230404886-A1 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. (US) | 2023-12-21 | — | — | US | disclosed |
| US-11766392-B2 | Minoxidil adjuvant therapies | Jupiter Wellness, Inc. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11628132-B2 | Minoxidil adjuvant therapies | Jupiter Wellness, Inc. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20220296486-A1 | Minoxidil Adjuvant Therapies | Jupiter Wellness, Inc. | 2022-09-22 | — | — | US | disclosed |
| EP-3257842-B1 | THERAPEUTIC USE OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2020-11-18 | — | — | EP | disclosed |
| EP-2474521-A1 | High purity degree 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides for use as medicaments and pharmaceutical formulations containing them | Newron Pharmaceuticals S.p.A. (IT) | 2012-07-11 | — | — | EP | disclosed |
| US-20120157712-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2012-06-21 | — | — | US | disclosed |
| US-8076515-B2 | Process for the production of 2-[4-(3- and 2-fluorobenzyloxy) benzylamino] propanamides | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-12-13 | — | — | US | disclosed |
| WO-2011134763-A1 | PROCESS FOR THE PRODUCTION OF RALFINAMIDE METHANESULFONATE SALTS OR THEIR R-ENANTIOMERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-11-03 | — | — | WO | disclosed |
| US-20100324141-A1 | HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES AND METHODS OF USE THEREOF | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-12-23 | — | — | US | disclosed |
| EP-2229351-A1 | PROCESS FOR THE PRODUCTION OF 2-Ý4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO¨PROPANAMIDES WITH HIGH PURITY DEGREE | Newron Pharmaceuticals S.p.A. (IT) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009074478-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-06-18 | — | — | WO | disclosed |
| US-20090156678-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-06-18 | — | — | US | disclosed |
| EP-2029524-A1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES | Newron Pharmaceuticals S.p.A. (IT) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007147491-A1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLU0R0BENZYL0XY) BENZYLAMIN0] PROPAN AMIDES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156678-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | PTMA, PSMB2, PDGFRA | SCN9A 407/4885MAOB 129/4885SCN3A 272/4885 |
| US-12527729-B2 | Minoxidil adjuvant therapies | RXRA, RXRB, RXRG | SCN9A 1256/4885MAOB 4202/4885SCN3A 1318/4885 |
| US-20100324141-A1 | HIGH PURITY 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES AND METHODS OF USE THEREOF | PDE7A, PDE8B, PDE9A | SCN9A 147/4885MAOB 53/4885SCN3A 130/4885 |
| US-12533309-B2 | Minoxidil adjuvant therapies | RXRG, RXRA, RXRB | SCN9A 2659/4885MAOB 4209/4885SCN3A 2244/4885 |
| US-20120157712-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDES | PTMA, PSMB2, PDGFRA | SCN9A 407/4885MAOB 129/4885SCN3A 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.